Delayed graft function: Risk factors and implications for renal allograft survival

Transplantation

Volumn 63, Issue 7, 1997, Pages 968-974

  Ojo, Akinlolu O ^a   Wolfe, Robert A ^b   Held, Philip J ^a,b   Port, Friedrich K ^a,b,c   Schmouder, Robert L ^a,c,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COLD INJURY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HOSPITALIZATION; HUMAN; ISCHEMIA; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; CADAVER; COHORT STUDIES; CRYOPRESERVATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INCIDENCE; KIDNEY; KIDNEY TRANSPLANTATION; MALE; ODDS RATIO; ORGAN PRESERVATION; PROGNOSIS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030903510     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199704150-00011     Document Type: Article

References (44)

1. Walaszewski J, Rowinski W, Pacholczyk M, et al. Multiple risk factor analysis of delayed graft function (ATN) after cadaveric transplantation: positive effect of lidocaine donor pretreatment. Transplant Proc 1991; 23(5): 2475.
2. Koning OH, van Bockel JH, van der Woude FJ, Persijn GG, Hermans J, Ploeg RJ. Risk factors for delayed graft function in University of Wisconsin solution preserved kidneys from multiorgan donors. European Multicenter Study Group on Organ Preservation. Transplant Proc 1995; 27(1): 752.
3. Corman J, Moukarzel M, Guttmann R, et al. Quebec Metro- Transplantation Multicenter Study on delayed graft function in kidney transplantation. Transplant Proc 1988; 20 (1 suppl 1): 428.
4. Shackleton CR, Keown PA, McLoughlin MG, et al. Cadaver kidney transplantation with minimal delayed function: experience with perioperative strategies to enhance initial renal allograft function. Transplant Proc 1995; 27(1): 1075.
5. Langley J, Vergne-Marini P, Dickerman RM, Brinker KR, Land G. Single center experience of the effect of delayed function on outcome in retransplant recipients of cadaveric renal allografts. Transplant Proc 1991; 23(2): 1757.
6. Michael HJ, Francos GC, Burke JF, et al. A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients [see comments]. Transplantation 1989; 48(5): 805.
7. Benvenisty AI, Cohen D, Stegall MD, Hardy MA. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function. Transplantation 1990; 49(2): 321.
8. Yokoyama I, Uchida K, Kobayashi T, Tominaga Y, Orihara A, Takagi H. Effect of prolonged delayed graft function on longterm graft outcome in cadaveric kidney transplantation. Clin Transplant 1994; 8 (2 Pt 1): 101.
9. Almond PS, Troppmann C, Escobar F, Frey DJ, Matas AJ. Economic impact of delayed graft function. Transplant Proc 1991; 23 (1 Pt 2): 1304.
10. Rosenthal JT, Danovitch GM, Wilkinson A, Ettenger RB. The high cost of delayed graft function in cadaveric renal transplantation. Transplantation 1991; 51(5): 1115.
11. Howard RJ, Pfaff WW, Brunson ME, et al. Delayed graft function is associated with an increased incidence of occult rejection and results in poorer graft survival. Transplant Proc 1993; 25 (1 Pt 2): 884.
12. Terasaki PI, Yuge J, Cecka JM, Gjertson DW, Takemoto S, Cho Y. Thirty-year trends in clinical kidney transplantation. In: Terasaki PI, ed. Clinical transplants 1993. Los Angeles: UCLA Tissue Typing Laboratory, 1993: 553.
13. Rocher LL, Landis C, Dafoe DC, Keyserling C, Swartz RD, Campbell DA Jr. The long-term deleterious effect of delayed graft function in cyclosporine-treated renal allograft recipients. Transplant Proc 1987; 19 (1 Pt 3): 2093.
14. Sanfilippo F, Vaughn WK, Spees EK, Lucas BA. The detrimental effects of delayed graft function in cadaver donor renal transplantation. Transplantation 1984; 38(6): 643.
15. Barry JM, Shively N, Hubert B, Hefty T, Norman DJ, Bennett WM. Significance of delayed graft function in cyclosporine- treated recipients of cadaver kidney transplants. Transplantation 1988; 45(2): 346.
16. Belitsky P, MacDonald AS, Gajewski J, Boudreau J, Bitter- Suermann H, Cohen A. Significance of delayed function in cyclosporine-treated cadaver kidney transplants. Transplant Proc 1987; 19 (1 Pt 3): 2096.
17. Cicciarelli TV, Sumrani N, DiBenedetto A, Hong JH, Sommer BG. Influence of race on delayed graft function and outcome in the cyclosporine era. Transplant Proc 1993; 25: 2460.
18. Cicciarelli T, Sumrani N, Delaney V, Hong JH, DiBenedetto A, Sommer BG. The influence of delayed renal allograft function on long-term outcome in the cyclosporine era. Clin Nephrol 1993; 39: 335.
19. Shoskes DA, Hodge EE, Goormastic M, Goldfarb DA, Novick AC. HLA matching determines susceptibility to harmful effects of delayed graft function in renal transplant recipients. Transplant Proc 1995; 27(1): 1068.
20. Troppmann C, Gillingham KJ, Benedetti E, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation: a multivariate analysis. Transplantation 1995; 59(7): 962.
21. Feldman HI, Gayner R, Berlin JA, et al. Delayed function reduces renal allograft survival independent of acute rejection. Nephrol Dial Transplant 1996; 11(7): 1306.
22. Troppmann C, Gillingham KJ, Gruessner RWG, et al. Delayed graft function in the absence of rejection has no long-term impact: a study of cadaver kidney transplant recipients with good graft function at 1 year after transplantation. Transplantation 1996; 61(9): 1331.
23. Tullius SG, Hancock WW, Heemann U, Azuma J, Tilney NL. Reversibility of chronic renal allograft rejection: critical effect of time after transplantation suggest both host immune dependent and independent phases of progressive injury. Transplantation 1994; 58: 93.
24. Shoskes DA, Halloran PF. Ischemic injury induces altered MHC gene expression in kidney by an interferon-gamma-dependent pathway. Transplant Proc 1991; 23 (1 Pt 1): 599.
25. Goes N, Urmson J, Ramassar V, Halloran PF. Ischemic acute tubular necrosis induces an extensive local cytokine response: evidence for induction of interferon-gamma, transforming growth factor-beta 1, granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. Transplantation 1995; 59(4): 565.
26. Goes N, Urmson J, Vincent D, Ramassar V, Halloran PF. Induction of major histocompatibility complex markers and inflammatory cytokines after ischemic injury to the kidney: lessons from interferon-gamma gene knockout mice. Transplant Proc 1995; 27(1): 771.
27. Schmouder RL, Stricter RM, Kunkel SL. Interferon-g regulation of human renal cortical epithelial cell-derived monocyte chemotactic peptide-1. Kidney Int 1993; 44: 1.
28. Merino GE, Buselmeier TJ, Kjellstrand CM. Postoperative chronic renal failure: a new syndrome? Ann Surg 1975; 182(1): 37.
29. Hida M, Saitoh H, Satoh T. Autopsy findings in postoperative acute renal failure patients, collected from the annals of pathological autopsy cases in Japan. Tokai J Exp Clin Med 1984; 9(5-6): 349.
30. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected] [letter] [published erratum appears in N Engl J Med 1989; 321(1): 63]. N Engl J Med 1989; 320(21): 1420.
31. Cole EH, Cattran DC, Farewell VT, et al. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection. Transplantation 1994; 57(1): 60.
32. Sutherland DE, Fryd DS, Strand M, Ascher N, Simmons RL, Najarian JS. Results of renal transplantation in diabetics at the University of Minnesota since 1979: including a comparison of outcome in diabetic and nondiabetic recipients randomized to cyclosporine versus azathioprine for immunosuppression. Transplant Proc 1984; 16(3): 629.
33. Brenner BM, Milford EL. Nephron underdosing: a programmed cause of chronic allograft failure. Am J Kidney Dis 1993; 21: 66.
34. Schmouder RL, Stricter RM, Wiggins RC, Chensue SW, Kunkel SI. In vitro and in vivo production of interleukin-8 (IL-8) in renal cortical epithelial cells. Kidney Int 1992; 41: 191.
35. Schmouder RL, Streiter RM, Walz A, Kunkel SL. Epithelial- derived neutrophil-activating factor-78 production in human renal tubule epithelial cells and in renal allograft rejection. Transplantation 1995; 59(1): 118.
36. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors [see comments]. N Engl J Med 1995; 333(6): 333.
37. Banhegyi C, Sauter T, Gnant M, Gotzinger P, Wamser P, Muhlbacher F. Transplantation of shipped full-house, HLA-identical kidneys versus local, poorly matched grafts: does a shorter cold ischemia time outweigh a poorer HLA match? Transplant Proc 1991; 23: 2610.
38. Salaman JR, Ross WB. Exchanging kidney transplants: is it worth it? Lancet 1987; 1: 1480.
39. Takiff H, Iwaki Y, Cecka M, Terasaki PI. The benefit and underutilization of sharing kidneys for better histocompatibility. Transplantation 1989; 47(1): 102.
40. Aswad S, Mann SL, Khetan U, et al. Omit HLA matching to attain shorter cold ischemia time. Transplant Proc 1993; 25(6): 3053.
41. Held PJ, Kahan BD, Hunsicker LG, et al. The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med 1994; 331: 765.
42. Takemoto S, Terasaki PI, Gjertson DW, Cecka JM. Equitable allocation of HLA-compatible kidneys for local pools and minorities [see comments]. N Engl J Med 1994; 331(12): 760.
43. United Network for Organ Sharing. 1994 Annual report of the U.S. Scientific Registry for Transplant Recipients and the Transplantation Network-transplant data: 1988-1993. Richmond, VA: United Network for Organ Sharing and the Division of Organ Transplantation, Bureau of Health Resources Development, Health Resources and Services Administration, U.S. Department of Health and Human Services, 1994.
44. Almond PS, Matas AJ, Canafax DM. Fixed-rate reimbursement fails to cover costs for patients with delayed graft function. Pharmacotherapy 1991; 11(5): 126S.